Drug Profile
Research programme: folate-targeted cancer therapeutics - FLAG Therapeutics
Alternative Names: Folate-targeted anticancer compounds - Duquesne/FLAG; FTAC - FLAG TherapeuticsLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Duquesne University
- Developer FLAG Therapeutics
- Class Small molecules
- Mechanism of Action Phosphoribosylglycinamide formyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 26 Apr 2021 Folate-targeted cancer therapeutics is in preclinical development in the US for Cancer (FLAG Therapeutics website, April 2021)
- 26 Apr 2021 FLAG Therapeutics has multiple patents pending for purine synthesis inhibitors (FLAG Therapeutics pipeline, April 2021)